Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 21;4(3):394-408.
doi: 10.1039/C5TB01613D. Epub 2015 Dec 1.

Light-Sensitive Ruthenium Complex-Loaded Cross-linked Polymeric Nanoassemblies for the Treatment of Cancer

Affiliations

Light-Sensitive Ruthenium Complex-Loaded Cross-linked Polymeric Nanoassemblies for the Treatment of Cancer

M Dickerson et al. J Mater Chem B. .

Abstract

This work focuses on improving the efficacy of photoactivatable Ru complexes for photodynamic therapy by employing cross-linked nanoassemblies (CNAs) as a delivery approach. The effects of complex photoactivation, hydrophobicity, and solution ionic strength and pH on complex loading and release from CNAs were analyzed. The cell cytotoxicity of CNA formulations was similar to free Ru complexes despite reduced or eliminated DNA interactions. The release rate and the amount of each Ru complex released (%) varied inversely with complex hydrophobicity, while the effect of solution ionic strength was dependent on complex hydrophobicity. Premature release of two photoactivatable prodrugs prior to irradiation was believed to account for higher activity in cells studies compared to DNA interaction studies; however, for photostable 1O2 generator-loaded CNAs this cannot explain the high cytotoxicity and lack of DNA interactions because release was incomplete after 48 hrs. The cause remains unclear, but among other possibilities, accelerated release in a cell culture environment may be responsible.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structures of Ru complexes a) [Ru(bpy)2(dmbpy)]Cl2 (1), b) [Ru(dmbpy)2(dip)]Cl2 (2), and c) [Ru(dip)3]Cl2
Figure 2
Figure 2
PEG (5k) (blue lines)-ASP (35 units) (red lines) CNA preparation. 1) PEG-ASP(H+) block copolymers were cross-linked (green lines) with diaminooctane (DAO) activated with diisopropylcarbodiimide (DIC)/ N-hydroxysuccinimide (NHS)/dimethylaminopyridine (DMAP); 2) ASP(H+) groups of PEG-ASP CNAs converted to ASP(Na+); 3) positively charged Ru complexes (red circles) were physically entrapped inside PEG-ASP CNAs through electrostatic interactions with ASP(Na+) groups.
Figure 3
Figure 3
a) Empty PEG-ASP CNA diameter determined by DLS, b) empty PEG-ASP CNA molecular weight estimated based on GPC, and c) 1- and 2-loaded CNA stability was determined by DLS (1-loaded PEG-ASP CNAs ( formula image) and 2-loaded PEG-ASP CNAs ( formula image)).
Figure 4
Figure 4
Photoejection kinetics of a) free 1, b) 1-loaded PEG-ASP CNAs, c) free 2, and d) 2-loaded PEG-ASP CNAs. The blue lines indicate the spectra of initial Ru complex prodrugs, red lines indicate final photoactivated product(s), and the green line in c) indicates a transition between the primary and secondary phases (t = 90 sec).
Figure 5
Figure 5
Percent of a) 1, b) 2, and c) 3 PEG-ASP CNA-entrapped Ru complexes released from 10K MWCO dialysis cassettes in PBS (pH 7.4) at 37 °C (PEG-ASP CNAs protected from light ( formula image) and light irradiated PEG-ASP CNAs ( formula image)) compared to free Ru complexes released from 10K MWCO dialysis cassettes ( formula image). Because 3 was a photostable Ru complex, release was only evaluated when protected from light. The MLCT peaks of the entrapped Ru complexes were monitored in order to determine the amount of each Ru complex remaining inside the PEG-ASP CNAs, and this was used to calculate the amount of Ru complexes released as a function of time (N = 3).
Figure 6
Figure 6
The effect of buffer ionic strength on release from PEG-ASP CNAs for a) 1, b) 2, and c) 3 (free complex ( formula image), dark phosphate buffer ( formula image), dark PBS ( formula image), light phosphate buffer ( formula image), and light PBS ( formula image)); d) shows a magnification of the rapid release of 3 from PEG-ASP CNAs when placed in a solution with low ionic strength (0 mM NaCl) (N = 3). Because 3 was a photostable Ru complex, release was only evaluated when protected from light.
Figure 7
Figure 7
The effect of phosphate buffer pH on complex release from PEG-ASP CNAs through 10K MWCO dialysis cassettes for a) 1, b) 2, and c) 3 (dark pH 6.0 ( formula image), dark pH 7.4 ( formula image), light pH 6.0 ( formula image), and light pH 7.4 ( formula image)) compared to the release of free complexes from 10K MWCO dialysis cassettes ( formula image) (N = 3). Because 3 was a photostable Ru complex, release was only evaluated when protected from light (N = 3).
Figure 8
Figure 8
Agarose gel electrophoresis of 40 μg/mL pUC19 plasmid (10 mM phosphate buffer, pH 7.4) with light-sensitive Ru complexes. The supercoiled plasmid form migrates at 2000 bp, relaxed circle form is ~4000 bp, and linear form is just below 3000 bp. Dose response profiles: a) free 1 in the dark and b) photoactivated (40 J/cm2; 200 W source (λ> 400 nm)), c) 1-loaded PEG-ASP CNAs in the dark and d) photoactivated, e) free 2 in the dark and f) photoactivated, g) 2-loaded PEG-ASP CNAs in the dark and h) photoactivated, i) free 3 in the dark and j) photoactivated, and k) 3-loaded PEG-ASP CNAs in the dark and l) photoactivated. Lanes 1 and 12, DNA molecular weight standard; lane 2, linear pUC19; lane 3, relaxed circle (Cu(phen)2 reaction with pUC19); lanes 4–11, 0, 7.5, 15, 30, 60, 120, 240, and 500 μM complexes.
Figure 9
Figure 9
UV/Vis absorbance spectra (hatched lines) and emission spectra (solid lines) in air-equilibrated diH2O (red) and deoxygenated (Ar purged) diH2O (black) for a) free 3, and b) 3-loaded PEG-ASP CNAs.

Similar articles

Cited by

References

    1. Howerton BS, Heidary DK, Glazer EC. Strained ruthenium complexes are potent light-activated anticancer agents. J Am Chem Soc. 2012;134:8324–8327. - PubMed
    2. Dickerson M, Sun Y, Howerton B, Glazer EC. Modifying charge and hydrophilicity of simple Ru(II) polypyridyl complexes radically alters biological activities: old complexes, surprising new tricks. Inorg Chem. 2014;53(19):10370–7. - PMC - PubMed
    1. Zhang CX, Lippard SJ. New metal complexes as potential therapeutics. Curr Opin Chem Biol. 2003;7:481–489. - PubMed
    2. Fricker SP. Metal based drugs: from serendipity to design. Dalton Trans. 2007;43:4903–4917. - PubMed
    3. Bruijnincx PCA, Sadler PJ. New trends for metal complexes with anticancer activity. Curr Opin Chem Biol. 2008;12:197–206. - PMC - PubMed
    4. Chen T, Liu Y, Zheng WJ, Liu J, Wong YS. Ruthenium polypyridyl complexes that induce mitochondria-mediated apoptosis in cancer cells. Inorg Chem. 2010;49:6366–6368. - PubMed
    5. Groessl M, Zava O, Dyson PJ. Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin. Metallomics. 2011;3:591–599. - PubMed
    1. Goldbach RE, Rodriguez-Garcia I, van Lenthe JH, Siegler MA, Bonnet S. N-acetylmethionine and biotin as photocleavable protective groups for ruthenium polypyridyl complexes. Chem Eur J. 2011;17:9924–9929. - PubMed
    2. Wachter E, Heidary DK, Howerton BS, Parkin S, Glazer EC. Light-activated ruthenium complexes photobind DNA and are cytotoxic in the phtodynamic therapy window. Chem Commun. 2012;48:9649–9651. - PubMed
    3. Frasconi M, Liu Z, Lei J, Wu Y, Strekalova E, Malin D, Ambrogio MW, Chen X, Botros YY, Cryns VL, Sauvage JP, Stoddart JF. Photoexpulsion of surface-grafted ruthenium complexes and subsequent release of cytotoxic cargos to cancer cells from mesoporous silica nanoparticles. J Am Chem Soc. 2013;135:11603–11613. - PMC - PubMed
    4. Hufziger KT, Thowfeik FS, Charboneau DJ, Nieto I, Dougherty WG, Kassel WS, Dudley TJ, Merino EJ, Papish ET, Paul JJ. Ruthenium dihydroxybipyridine complexes are tumor activated prodrugs due to low pH and blue light induced ligand release. J Inorg Biochem. 2014;130:103–111. - PMC - PubMed
    1. Novakova O, Kasparkova J, Vrana O, van Vliet PM, Reedijk J, Brabec V. Correlation between cytotoxicity and DNA binding of polypyridyl ruthenium complexes. Biochemistry. 1995;34:12369–12378. - PubMed
    2. Kladjner M, Hebraud P, Sirlin C, Gaiddon C, Harlepp S. DNA binding to an anticancer organo-ruthenium complex. J Phys Chem. 2010;114:14041–14047. - PubMed
    3. Heidary DK, Glazer EC. A light-activated metal complex targets both DNA and RNA in a fluorescent in vitro transcription and translation assay. ChemBioChem. 2014;15:507–511. - PubMed
    1. Grover N, Welch TW, Fairley TA, Cory M, Thorp HH. Covalent Binding of Aquaruthenium complexes to DNA. Inorg Chem. 1994;33:3544–3548.
    2. Allardyce CS, Dyson PJ. Ruthenium in medicine: Current clinical uses and future prospects. Platinum Metals Rev. 2001;45:62–69.
    3. Lentzen O, Moucheron C, Kirsch-De Mesmaeker A. Metallotherapeutic drugs and metal-based diagnostic agents. John Wiley & Sons, Ltd; 2005. 44Ru Perspectives of ruthenium complexes in cancer therapy; pp. 359–378.
    4. Boerner LJK, Zaleski JM. Metal complex-DNA interactions: from transcription inhibition to photoactivated cleavage. Curr Opin Chem Biol. 2005;9:135–144. - PubMed

LinkOut - more resources